Education
About Us
Working with TipRanks
Follow Us
Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
ALA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.21
Previous CloseN/A
Volume194.12K
Average Volume (3M)2.22M
Market Cap
AU$104.18M
Enterprise ValueAU$124.20M
Total Cash (Recent Filing)AU$12.71M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 27, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,183,870,600
10 Day Avg. Volume1,408,386
30 Day Avg. Volume2,224,030
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)76.03
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Arovella Therapeutics Limited News
PremiumCompany Announcements
Arovella Therapeutics Cancels Proposed Securities Issue
PremiumCompany Announcements
Arovella Therapeutics Cancels Proposed Securities Issuance
PremiumCompany Announcements
Arovella Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Arovella Therapeutics Announces Proposed Securities Issue---
Options Prices
Currently, No data available
---
Ownership Overview
1.02% Insiders
―
Mutual Funds
― Other Institutional Investors
98.98% Public Companies and
Individual Investors
ALA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.07 and its highest was AU$0.21 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$104.18M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
Arovella Therapeutics Limited’s upcoming earnings report date is Aug 27, 2025 which is in 124 days.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Feb 26, 2025. The company reported -AU$0.001 earnings per share for the quarter, beating the consensus estimate of -AU$0.002 by AU$0.001.
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate is >-0.01.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,183,870,600 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -AU$0.001 in its last earnings report, beating expectations of -AU$0.002. Following the earnings report the stock price went down -30%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
---
Arovella Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ALA Sentiment 94%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.91%
12-Months-Change
Fundamentals
Return on Equity
-85.35%
Trailing 12-Months
Asset Growth
137.38%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
---
Technical Analysis
Opthea Limited
―
Cynata Therapeutics Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Race Oncology Ltd.
―
---